New FMI Study Underscores Pivotal Role of Collaborations in Formulating Innovative Sustained Release Excipients

New FMI Study Underscores Pivotal Role of Collaborations in Formulating Innovative Sustained Release Excipients

PR Newswire

VALLEY COTTAGE, New York, November 26, 2018

VALLEY COTTAGE, New York, November 26, 2018 /PRNewswire/ --

A recently released global market intelligence outlook on sustained release excipients forecasts the revenue through sustained release excipients to surpass a million dollar value by this year's end, of which just-under 1/3rd share belongs to North America.

     (Logo: )

As a growing number of existing international patents are expiring and the prevalence of orthopedic disorders is increasing on the flipside, drug formulations and thereby sustained release excipients are constantly witnessing an impressive manufacturing outlook.

Research identifies the largest revenue shareholding categories in sustained release excipients marketplace on the basis of product type, end user, and route of administration.

A sample of this report is available upon request @

"The top five players leading the competition in global sustained release excipients landscape account for a collective revenue share of over 50%, whereas a number of relatively small companies represent the rest. A majority of competitors have a limited offering portfolio and significantly depend on product differentiation for an edge in niche treatment areas," explains a senior research analyst. "Product innovation and market expansion have been the top developmental strategies of companies so far, which are now complemented with strategic partnerships," the analyst adds further.

Multi-level Partnerships - The Key to Delivering Top Notch Excipient Formulations 

FMI underlines the critical role of strategic collaborations - between formulators of sustained release excipients and stakeholders across the value chain - in shaping growth of brands as well as the entire sustained release excipients ecosystem.

While partnerships are expected to prominently focus on spotting the key challenges facing manufacturers, continued education about functionality, variability, and consistency of sustained release excipients is also be an important objective. Drug product manufacturers working in tandem with formulators of sustained release excipients is helping companies deliver best-in-class solutions addressing the most prominent pull factors associated with sustained release excipients.

Preview Analysis On Sustained Release Excipients Market Segmentation By Product Type - Gelatin based Sustained Release Excipients Polymer based Sustained Release Excipients, minerals based Sustained Release Excipients, Sugars based Sustained Release Excipients, alcohol based Sustained Release Excipients, chitosan based Sustained Release Excipients; Route of Administration - oral, Injectable, Vaginal, and Ophthalmic:

To best grasp real-time market needs, sustained release excipient formulators are most likely to strengthen interaction with end-use customers. This move offers a dual advantage as a developmental strategy - by helping manufacturers precisely understand and address the challenges facing pharmaceutical markets and stimulating development of new excipient formulations that tap into evolving needs.

A recent deal (2017) involving the combination of The Dow Chemical Company-DuPont-FMC (Health & Nutrition) has been a classic example of collaborative operation, involving channel partners as well as customers.

Request Report TOC @

More from Healthcare, Pharmaceuticals and Medical devices: 

About Us 

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Browse More Healthcare, Pharmaceuticals and Medical devices

Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44(0)20-7692-8790
Press Office:

FMI Blog:


Voltar noticias em Inglês